Dr. Jenny Kanter has been awarded an Innovative Basic Science Award from the American Diabetes Association for her project entitled “Diabetes and Myocardial Infarction – Do They Synergize to Accelerate Atherosclerosis?” This 3-year project will study the mechanisms whereby immune cells accumulate in the artery wall and the role it plays in diabetes-accelerated cardiovascular disease. Dr. Kanter is a Research Assistant Professor of Medicine, Division of Metabolism, Endocrinology and Nutrition.
Dr. Chang Yeop Han, PhD, is first author and Dr. Alan Chait, MD, is senior author on the article article entitled “Serum amyloid A impairs the anti-inflammatory properties of HDL”, published in the December 2015 issue of The Journal of Clinical Investigation. The article reports findings indicating that inflammation results in a loss of the antiinflammatory properties of HDL on adipocytes, which appears to partially result from the SAA component of HDL binding to cell-surface proteoglycans, thereby preventing access of HDL to the plasma membrane. Other UW Diabetes Institute investigators co-authoring the paper include Chongren Tang, PhD, Baohai Shao, PhD, Savitha Subramanian, MD, Tomas Vaisar, PhD and William Osborne, PhD.
The Diabetes Research Center (DRC) is soliciting applications for the Pilot & Feasibility and Stroum Graduate Fellowship Awards. The calls are attached and also available at the DRC website: https://depts.washington.edu/diabetes/currentfundingapplication
Letters of Intent and reviewer nomination forms must be submitted using the online forms and are due by January 04, 2016. The deadline for applications is February 16, 2016.
DOCE Director Michael Schwartz, MD and Novo Nordisk collaborate on exploring the role of the brain in regulating blood glucose and obesity
Dr. Michael Schwartz is collaborating with Novo Nordisk on a three-year project to explore the role of the brain in regulating blood glucose and obesity. The collaboration aims to understand factors mediating brain control of blood glucose and appetite with the ultimate goal of developing new therapeutic agents for the treatment of diabetes and obesity. The research will be conducted at UW Medicine’s South Lake Union research campus in Seattle, Washington and at Novo Nordisk’s research facilities in Måløv, Denmark. Over the next three years, Dr. Schwartz and his team together with Novo Nordisk researchers will conduct a research program on the effect of known hormonal factors working in the brain to regulate whole body glucose metabolism and appetite. Dr. Schwartz is the Robert H. Williams Endowed Chair in Medicine, Professor, Division of Metabolism, Endocrinology and Nutrition.
Read the full press release here
Dr. Michael Schwartz was featured in a recent Sigma Nutrition.com podcast: SNR #89: Dr. Michael Schwartz – Role of the Brain in Obesity, Insulin Resistance and Type 2 Diabetes Pathogenesis. Click this link to access the full episode.
Dr. Bornfeldt has been awarded a new R01 from the NIH/NHLBI for her project entitled Obesity and Arterial Metabolism. The overall hypothesis is that expression of the glucose transporter GLUT1 is of critical importance for the obesity-induced arterial metabolic signature, smooth muscle cell phenotype, and obesity-accelerated atherosclerosis. Dr. Bornfeldt is a Professor of Medicine in the Division of Metabolism, Endocrinology and Nutrition, Professor of Pathology and the Deputy Director of the Diabetes Research Center.
NHLBI Renews Cardiovascular Disease and Diabetes Program Project (PI: Karin Bornfeldt, DOCE Associate Director)
The Cardiovascular Disease and Diabetes Program Project was recently renewed for five years, receiving a total of $11.8 million from the National Heart, Lung, and Blood Institute. The focus of the program project is to investigate whether diabetes causes high-density lipoprotein to lose its cardioprotective effects and whether this contributes to the increased cardiovascular disease risk associated with diabetes. This long-standing program project was originally awarded in 1958 with Robert H. Williams as PI. Edwin L. Bierman became PI in 1975, and Alan Chait served as PI from 1995 to 2013. Karin Bornfeldt became PI in 2013. The program includes four projects and three core units. Project Leaders are Jay Heinecke, Alan Chait and Karin Bornfeldt (DOCE), and Ira Goldberg and Edward Fisher, New York University. Core directors are Karin Bornfeldt, Tomas Vaisar (DOCE) and Kevin O’Brien (UW Medicine).
Drs. Wang Wang and Ian Sweet have been awarded an American Diabetes Association Innovative Award for their project entitled ‘Source and sites of action of hydrogen peroxide in mitochondria and cytosol of pancreatic islets’. The generation of hydrogen peroxide by the islet is associated with both the stimulation of insulin secretion and destruction of islet cells. Therefore, understanding the factors that control its production and action is critical for understanding how diabetes develops and how to treat the disease. The American Diabetes Association plays an important role in funding innovative pilot projects that generate proof of concept data. Dr. Sweet is an Associate Research Professor of Medicine in the Division of Metabolism, Endocrinology and Nutrition. Dr. Wang is an Assistant Professor of Anesthesiology and Pain Medicine.
Dr. Ian Sweet has been awarded an NIH Small Business Technology Transfer (STTR) award for his project entitled ‘Continuous measurement of cell growth as an optimal tool in drug toxicity testing’. The NIH STTR program allows US-owned and operated small businesses to engage in federal research and development (R&D) that has a strong potential for commercialization. Dr. Sweet’s project aims to develop a systematic and ultra-sensitive in vitro approach for measuring drug toxicity. Dr. Sweet is an Associate Research Professor of Medicine in the Division of Metabolism, Endocrinology and Nutrition.
Dr. Michael Schwartz’ research has been featured in the current issue of UW Medicine Magazine. The article, entitled “Diabetes & Obesity via the Brain” focuses on the Schwartz Laboratory’s use of optogentics to understand the neurocircuitry activated in diabetes with the goal to develop new opportunities to treat or prevent the disease. DOCE researchers Gregory Morton, PhD and Thomas Meek, PhD are also featured in the article. Click here to view the full article. Dr. Schwartz is the RH Williams Endowed Chair in Medicine, Professor of Medicine, Division of Metabolism, Endocrinology and Nutrition.